In 2012, Memorial Sloan-Kettering Cancer Center in New York began work on an adviser to recommend cancer treatments. Dr. Mark Kris, a Sloan-Kettering oncologist, said an early version of the Watson tool could be used on patients later this year if it passes tests.
At his office, he pulled out an iPad and showed a screen from Watson that listed three potential treatments. Watson was less than 32% confident that any of them were correct. "Just like cancer, it is much more complex than we thought," Dr. Kris said.
Watson may start really outperform humans when his strength - the ability to ingest and process/correlate huge amounts of, probably with not completely understood relevance, information, like full DNA sequence of a patient, etc... - will be fully utilized, and some previously unknown to humans patterns start to emerge.
Comments
IBM Struggles to Turn Watson Computer Into Big Business Revenue Is Far From Company's Ambitious Targets:
http://online.wsj.com/news/articles/SB1000142405270230488710...
In 2012, Memorial Sloan-Kettering Cancer Center in New York began work on an adviser to recommend cancer treatments. Dr. Mark Kris, a Sloan-Kettering oncologist, said an early version of the Watson tool could be used on patients later this year if it passes tests.
At his office, he pulled out an iPad and showed a screen from Watson that listed three potential treatments. Watson was less than 32% confident that any of them were correct. "Just like cancer, it is much more complex than we thought," Dr. Kris said.
Watson may start really outperform humans when his strength - the ability to ingest and process/correlate huge amounts of, probably with not completely understood relevance, information, like full DNA sequence of a patient, etc... - will be fully utilized, and some previously unknown to humans patterns start to emerge.